Disc Medicine, Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Disc Medicine, Inc. pe ratio for the quarter ending 2026-06-30 was -11.4, a change of 1.23 year-over-year.
- Disc Medicine, Inc. pe ratio for the quarter ending 2026-03-31 was -10.11, a change of 4.62 year-over-year.
- Disc Medicine, Inc. pe ratio for the quarter ending 2025-12-31 was -14.18, a change of 3.13 year-over-year.
- Disc Medicine, Inc. pe ratio for the quarter ending 2025-09-30 was -12.77, a change of 1.36 year-over-year.
- Disc Medicine, Inc. pe ratio for fiscal 2026 was -11.4.
- Disc Medicine, Inc. pe ratio for fiscal 2025 was -14.18, a change of 3.13 from fiscal 2024.
- Disc Medicine, Inc. pe ratio for fiscal 2024 was -17.31, a change of 1.1 from fiscal 2023.
- Disc Medicine, Inc. pe ratio for fiscal 2023 was -18.41, a change of -11.02 from fiscal 2022.
- Available history
- 2020-12-31 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |